Jennifer Shike 2024 - square.jpg

Jennifer Shike

As the brand leader of Farm Journal’s PORK and host of “The PORK Podcast,” Jennifer Shike pairs her deep animal science expertise with a heart for the people in the pork industry. Her work is a vital resource on swine health and biosecurity, reporting on threats such as PRRS, PED and African swine fever. By keeping a close watch on national and state policy, she translates trade deals, California’s Proposition 12, environmental regulations and farm bill updates into what they mean for American pork producers.

Latest Stories
Renowned air quality expert and CLEAR Center director Frank Mitloehner takes the helm of UC Davis’ premier Department of Animal Science to lead its global mission in agricultural research and environmental sustainability.
A new study confirms that international red meat demand accounted for over 600 million bushels of grain usage in 2025, significantly increasing the per-bushel value for American corn and soybean farmers.
By automating repetitive data tasks, artificial intelligence allows farm teams to spend less time behind a screen and more time focusing on animal husbandry and field work.
Years after her story first touched the agriculture industry, a suicide attempt survivor reflects on the reality of long-term healing and the power of uncomfortable conversations.
Texas A&M veterinarians document the first cases of ractopamine toxicity in canines, emphasizing the need for rapid treatment and specialized cardiac care.
In a major legislative milestone, the House-passed H.R. 7567 offers a roadmap for the next five years of American agriculture.
U.S. Customs and Border Protection stops dangerous products from entering the country to protect U.S. agriculture.
The Meat Institute’s latest brief empowers U.S. producers to replace generic global averages with precise, peer-reviewed data that reflects modern efficiency.
While global production climbed in 2025, the latest Alltech survey highlights a diverging landscape of North American contraction and rapid commercialization in Africa and Asia.
New reports highlight the concerning transboundary spread of a new serotype that evades current vaccines and increases the risk of introduction to the U.S.